Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 201
Filter
1.
J. bras. nefrol ; 42(2): 201-210, Apr.-June 2020. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1134814

ABSTRACT

Abstract Introduction: Renal fibrosis is the end point of a process that begins at transplant, with ischemia reperfusion and early inflammation, and progresses over time with immunological and non-immunological phenomena. Early identification of morphological markers and intervention could improve graft function and survival. Objective: to evaluate the correlation between intensity and specificity of pre-transplant anti-HLA antibodies and kidney allograft pathology in order to identify early risk factors or markers of allograft dysfunction. Methods: A retrospective cohort of kidney transplant recipients with pre-transplant anti-HLA antibodies who underwent graft biopsy within the first two years post-transplant was divided into two groups according to the specificity of anti-HLA antibodies: nonspecific (non-DSA, n = 29) and specific (DSA+, n = 16). Kidney graft pathology, renal function, and proteinuria were analyzed. Results: general characteristics were similar in both groups, except for the higher dose of thymoglobulin in DSA+ group (p < 0.05). The non-DSA group had higher scores for glomerulosclerosis, interstitial inflammation (i) and interstitial fibrosis (ci) (p < 0.05) and higher incidence of cell-mediated acute rejection. No statistical difference in incidence of antibody-mediated rejection, renal function, and proteinuria was observed during follow up. Discussion and conclusions: the difference in inflammation scores and interstitial fibrosis may be associated to the higher incidence of acute cell-mediated rejection and polyomavirus nephropathy in the Non-DSA group. We also should take into account the protective effect of higher doses of thymoglobulin, reducing ischemia reperfusion injury in the DSA+ group. The short follow-up might have been insufficient to detect long-term changes in allograft tissue, renal function, and proteinuria.


Resumo Introdução: A fibrose renal é o desfecho de um processo iniciado no transplante, com reperfusão, isquemia e inflamação precoce, que progride ao longo do tempo com fenômenos imunológicos e não imunológicos. A identificação de marcadores morfológicos e a intervenção precoce poderiam melhorar a função e a sobrevida do enxerto. Objetivo: Avaliar a correlação entre intensidade e especificidade de anticorpos anti-HLA pré-transplante alterações histológicas do enxerto renal, de forma a identificar fatores de risco ou marcadores de disfunção precoces do aloenxerto. Métodos: O presente estudo incluiu uma coorte retrospectiva de receptores de transplante renal sensibilizados com anticorpos anti-HLA no pré-transplante submetidos a biópsia de enxerto nos primeiros dois anos após o transplante. Os grupos foram divididos em função da especificidade dos anticorpos anti-HLA: sem anticorpos doador-específicos (não-DSA, n = 29) e com anticorpos doador-específicos (DSA+, n = 16). Alterações histológicas do enxerto renal, função renal e proteinúria foram analisados. Resultados: Os dois grupos tinham características gerais semelhantes, exceto pela dose mais elevada de timoglobulina administrada nos indivíduos do grupo DSA+ (p < 0,05). O grupo não-DSA teve escores mais elevados de glomeruloesclerose, inflamação intersticial (i) e fibrose intersticial (ci) (p < 0,05), além de maior incidência de rejeição celular aguda (RCA). Não foi observada diferença estatística na incidência de rejeição mediada por anticorpos, função renal ou proteinúria durante o seguimento. Discussão e Conclusões: A diferença nos escores de inflamação e fibrose intersticial pode estar associada à maior incidência de RCA e nefropatia por poliomavírus no grupo não-DSA. Devemos considerar ainda o efeito protetor das doses mais elevadas de timoglobulina na redução da lesão por isquemia-reperfusão no grupo DSA+. O curto período de seguimento pode ter sido insuficiente para detectar alterações de longo prazo no tecido do aloenxerto, função renal e proteinúria.


Subject(s)
Humans , Male , Female , Middle Aged , Kidney Transplantation/adverse effects , Transplant Recipients , Graft Rejection/immunology , HLA Antigens/immunology , Kidney/immunology , Antibodies/blood , Proteinuria/diagnosis , Time Factors , Biopsy , Fibrosis/etiology , Reperfusion Injury/prevention & control , Retrospective Studies , Immunosuppression Therapy/methods , Treatment Outcome , Disease Progression , Preoperative Period , Graft Rejection/pathology , Kidney/blood supply , Antibody Specificity
2.
Rev. gastroenterol. Perú ; 40(2): 127-135, abr-jun 2020. tab, graf
Article in English | LILACS | ID: biblio-1144650

ABSTRACT

ABSTRACT Background: Evidence indicates that low-grade inflammation can alter gastrointestinal motor and sensory function and might contribute to the genesis of symptoms in IBS. Objective: To examine relationships between IBS, disease antibodies and cytokine titers in celiac patients and a control group. Materials and methods: IBS, CD activity and serum levels of IL-6, IL-8 and IL12/23p40 were determined in celiac patients and controls. Results: 123 celiac patients were included, 89% were female. 59% demonstrated disease activity and 32% met IBS criteria. Prevalence of IBS was not different between patients who adhered or did not adhere to GFD as well as between patients with or without positive antibodies. Celiac patients had increased levels of IL-6, IL-8 and IL12/23p40 as compared to controls. Higher levels of cytokines were found in celiac patients with IBS than in those without IBS. No difference in levels of cytokines was found between patients with and without CD positive antibodies. A significant negative correlation between the mental component of QoL and IL-6 and IL12/23p40 levels was found, but not with IL-8. Conclusion: Higher levels of inflammatory cytokines were found in CD patients with IBS than in either those without IBS or controls, indicating that IBS symptoms are associated with an increase in the inflammatory response and a decrease in quality of life of CD patients. These differences in cytokine levels were not related to CD antibodies status suggesting that IBS, in CD, is related to a different inflammatory process than that which is relevant to CD.


RESUMEN Antecedentes: la evidencia indica que la inflamación de bajo grado puede alterar la función motora y sensorial gastrointestinal y puede contribuir a la aparición de síntomas en el SII. Objetivo: Examinar la relación entre SII, anticuerpos contra enfermedades y títulos de citocinas en pacientes celíacos y un grupo de control. Materiales y métodos: se determinaron los síntomas de SII, actividad de CD y niveles séricos de IL-6, IL-8 e IL12 / 23p40 en pacientes celíacos y controles. Resultados: se incluyeron 123 pacientes celíacos, el 89% eran mujeres. El 59% demostró actividad de la enfermedad y el 32% cumplió con los criterios del SII. La prevalencia del SII no fue diferente entre los pacientes que se adhirieron o no se adhirieron a GFD, así como entre los pacientes con o sin anticuerpos positivos. Los pacientes celíacos tenían niveles aumentados de IL-6, IL-8 e IL12 / 23p40 en comparación con los controles. Se encontraron niveles más altos de citocinas en pacientes celíacos con SII que en aquellos sin SII. No se encontraron diferencias en los niveles de citocinas entre pacientes con y sin anticuerpos CD positivos. Se encontró una correlación negativa significativa entre el componente mental de la calidad de vida y los niveles de IL-6 e IL12 / 23p40, pero no con IL-8. Conclusión: Se encontraron niveles más altos de citocinas inflamatorias en pacientes con EC con SII que en aquellos sin SII o controles, lo que indica que los síntomas del SII están asociados con un aumento en la respuesta inflamatoria y una disminución en la calidad de vida de los pacientes con CD. Estas diferencias en los niveles de citocinas no estaban relacionadas con el estado de los anticuerpos contra la CD, lo que sugiere que el SII, en la CD, está relacionado con un proceso inflamatorio diferente al que es relevante para la CD.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Celiac Disease/complications , Celiac Disease/immunology , Interleukin-8/blood , Interleukin-6/blood , Interleukin-12/blood , Irritable Bowel Syndrome/blood , Irritable Bowel Syndrome/complications , Antibodies/blood , Cross-Sectional Studies
3.
Einstein (Säo Paulo) ; 18: eRC4582, 2020.
Article in English | LILACS | ID: biblio-1039732

ABSTRACT

ABSTRACT The correct identification of erythrocyte antibodies is fundamental for the searching for compatible blood and haemolytic transfusion reactions prevention. Antibodies against antigens of high prevalence are difficult to identify because of the rarity of their occurrence and unavailability of negative red cells for confirmation. We report a case of 46-years-old woman, diagnosed with hemoglobinopathy, and who had symptomatic fall in hemoglobin levels (5.3g/dL) after blood transfusion suggestive of transfusion reaction. The patient's blood type was O RhD-positive. Irregular antibody screening was positive and demonstrated a panreaction against all erythrocytes tested, but this result was not reactive with dithiothreitol. Using negative red cells for antigens of high prevalence of our inventory we could identify in the serum of the same erythrocytes an anti-Holley antibody associated with anti-E. Molecular analysis confirmed that the patient was negative for E and Holley antigens. The crossmath with compatible units confirmed the results. Holley is a high prevalence antigen of the Dombrock blood system whose negative phenotype is extremely rare in all populations and is associated with hemolytic transfusion reactions. This is an antibody that is difficult to identify because laboratories need to have experience in solving complex cases, and have available a large stock of rare sera and erythrocytes, as well other tools such as enzymes, thiol reagents and molecular tests. The correct identification of a rare antibody is initial and mandatory for searching of compatible donors, and to guarantee a satisfactory transfusional support.


RESUMO A correta identificação dos anticorpos eritrocitários é fundamental na busca de sangue compatível e na prevenção das reações transfusionais hemolíticas. Anticorpos contra antígenos de alta prevalência são de difícil identificação, devido à raridade de sua ocorrência e à indisponibilidade de hemácias negativas para sua confirmação. Apresentamos aqui o caso de uma paciente do sexo feminino, 46 anos, com diagnóstico de hemoglobinopatia, que apresentou queda sintomática dos níveis de hemoglobina (5,3g/dL) após transfusão sanguínea, sugestiva de reação transfusional. O tipo sanguíneo da paciente era O RhD-positivo. A pesquisa de anticorpos irregulares foi positiva, demonstrando panreação contra todos os eritrócitos testados, mas não reativo ao ditiotreitol. Utilizando hemácias selecionadas negativas para antígenos de alta prevalência do nosso inventário, foi possível identificar no soro da mesma um anticorpo anti-Holley associado a um anti-E. A análise molecular confirmou que a paciente era negativa para os antígenos E e Holley, e as provas de compatibilidade com unidades fenotipadas confirmaram os resultados. Holley é um antígeno de alta prevalência do sistema sanguíneo Dombrock, cujo fenótipo negativo é extremamente raro em todas as populações e está associado a reações transfusionais hemolíticas. Trata-se de anticorpo de difícil identificação, pois os laboratórios precisam ter experiência na resolução de casos complexos, grande estoque de soros e eritrócitos raros, além de outras ferramentas, como enzimas, reagentes tiol e testes moleculares. A identificação correta de um anticorpo raro é inicial e obrigatória para a busca de doadores compatíveis, garantindo um suporte transfusional satisfatório.


Subject(s)
Humans , Female , Blood Group Incompatibility/immunology , Blood Group Antigens/immunology , Transfusion Reaction/immunology , Antibodies/immunology , Immunoglobulins/blood , Erythrocytes/immunology , Hematologic Tests/methods , Isoantibodies/immunology , Middle Aged , Antibodies/blood
4.
Adv Rheumatol ; 60: 45, 2020. tab, graf
Article in English | LILACS | ID: biblio-1130781

ABSTRACT

Abstract Background Anti-ribosomal P (anti-Rib-P) antibody is a specific serological marker for systemic lupus erythematosus (SLE) and routinely tested by targeting the common epitope of three ribosomal proteins of P0, P1 and P2. This study aimed to investigate if testing antibodies against individual ribosomal protein, but not the common epitope, is required to achieve the best diagnostic benefit in SLE. Methods The study included 82 patients with SLE and 22 healthy donors. Serum antibodies were determined by ELISA and immunoblot. Results The prevalence of each antibody determined by ELISA was 35.4% (anti-Rib-P), 45.1% (anti-Rib-P0), 32.9% (anti-Rib-P1) and 40.2% (anti-Rib-P2) at 99% specificity, respectively. Of 53 patients with negative anti-Rib-P antibody, 21 (39.6%) were positive for anti-Rib-P0, 9 (17.0%) for anti-Rib-P1 and 12 (22.6%) for anti-Rib-P2 antibody. The positive rate of anti-Rib-P antibody detected by ELISA was close to the results by immunoblot (33.4%). Patients with any of these antibodies were featured by higher disease activity and prevalence of skin rashes than those with negative antibodies. Moreover, each antibody was particularly related to some clinical and laboratory disorders. The distribution of subclasses of IgG1-4 was varied with each antibody. Anti-Rib-P0 IgG1 and IgG3 were strongly correlated with disease activity and lower serum complement components 3 and 4. Conclusions Anti-Rib-P antibody is not adequate to predict the existence of antibodies against ribosomal P0, P1 and P2 protein. The examination of antibodies against each ribosomal protein is required to achieve additional diagnostic benefit and to evaluate the association with clinical and serological disorders as well.(AU)


Subject(s)
Humans , Ribosomal Protein L10/blood , Lupus Erythematosus, Systemic/diagnosis , Antibodies/blood , Enzyme-Linked Immunosorbent Assay/instrumentation , Immunoblotting/instrumentation
5.
Acta bioquím. clín. latinoam ; 53(3): 323-330, set. 2019. tab
Article in Spanish | LILACS | ID: biblio-1038102

ABSTRACT

El rastreo de anticuerpos anti-eritrocitarios es una de las pruebas pretransfusionales más importantes en medicina transfusional por su aporte en la prevención de reacciones adversas luego de la administración de hemocomponentes. Sin embargo, no todos los bancos de sangre ecuatorianos han incluido esta prueba en sus protocolos de trabajo. Para demostrar su importancia se realizó el presente estudio cuyo propósito fue alertar al sistema nacional de salud sobre la existencia de aloinmunización en la población de donantes de sangre. Se estableció una prevalencia de anticuerpos anti-eritrocitarios del 0,27% y se identificó una mayor frecuencia en el género femenino. Los anticuerpos identificados estuvieron relacionados con los sistemas eritrocitarios Rh (RH), Kell (KEL), Duffy (FY) y Kidd (JK). Una de las limitaciones para la inclusión de esta prueba en los bancos de sangre y servicios de medicina transfusional es el elevado costo de los reactivos y la falta de paneles de células eritrocitarias de composición homocigota y heterocigota para la identificación de anticuerpos anti-eritrocitarios nativos, situación que constituye una oportunidad para que el Ministerio de Salud Pública del Ecuador promueva mejores estrategias para la importación de reactivos, reducción de costos y disponibilidad de paneles de células.


The screening of anti-erythrocyte antibodies is one of the most important pretransfusion tests in transfusion medicine because of its contribution to the prevention of adverse reactions after the administration of blood components, however not all blood banks in Ecuador have included this test in their work protocols. This study has the purpose to alert the national health system about the existence of alloimmunization in the blood donour population. A prevalence of anti-erythrocyte antibodies of 0.27% was established, with a higher frequency being found in the female gender. The identified antibodies are related to the erythrocyte systems Rh (RH), Kell (KEL), Duffy (FY) and Kidd (JK). One of the limitations for the inclusion of this test in blood banks and transfusion medicine services is the excessive cost of serological and gel methodology reagents, and the lack of homozygous and heterozygous erythrocyte cell panels for the identification of native anti-erythrocyte antibodies. That situation constitutes an opportunity for the Ministry of Public Health of Ecuador to promote better strategies for the imports of reagents, cost reduction and availability in the country.


O rastreamento de anticorpos anti-eritrocitários é um dos testes pré-transfusão mais importantes na medicina transfusional pela sua contribuição na prevenção de reações adversas após a administração de componentes sanguíneos. No entanto, nem todos os bancos de sangue do Equador tem incluído esse teste em seus protocolos de trabalho. Para demonstrar a sua importância, foi realizado o presente estudo que teve como objetivo alertar o sistema nacional de saúde sobre a existência de aloimunização na população de doadores de sangue. Foi estabelecida uma prevalência de anticorpos anti-eritrocitários de 0,27%, identificando maior frequência no sexo feminino. Os anticorpos identificados estiveram relacionados com os sistemas eritrocitários Rh (RH), Kell (KEL), Duffy (FY) e Kidd (JK). Uma das limitações para a inclusão destes testes em bancos de sangue e serviços de medicina da transfusão é o alto custo dos reagentes, além da falta de painéis de células eritrocitárias de composição homozigótica e heterozigótica para a identificação de anticorpos anti-eritrocitários nativos, situação que constitui uma oportunidade para que o Ministério da Saúde Pública do Equador promova melhores estratégias para a importação de reagentes, redução de custos e disponibilidade de painéis de células.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Blood Donors/statistics & numerical data , Antibodies/blood , Blood Transfusion , Epidemiology, Descriptive , Prevalence , Retrospective Studies , Ecuador , Erythrocytes
6.
Acta bioquím. clín. latinoam ; 53(3): 353-360, set. 2019. graf, tab
Article in Spanish | LILACS | ID: biblio-1038106

ABSTRACT

La neurocisticercosis (NCC) es la localización en el sistema nervioso central (SNC) humano de la parasitosis provocada por el estadio larvario de la Taenia solium, el cisticerco, que prevalece en áreas urbanas y rurales y constituye un problema de salud pública. El diagnóstico puede efectuarse por exploración imagenológica del SNC con resonancia magnética o tomografía axial computarizada, no siempre disponible, y por pruebas de inmunoensayo (EIA) en sangre, que aportan al diagnóstico rapidez, bajo costo y transferibilidad. Para evaluar su capacidad diagnóstica y validar la precisión de la técnica de ELISA (ensayo inmunoabsorbente ligado a enzimas), en la detección de anticuerpos anti-cisticercos en sueros humanos, se diseñó una seroteca en forma aleatoria y en doble ciego, y se realizó el ELISA con las muestras, utilizando placas sensibilizadas con antígenos obtenidos del fluido vesicular de cisticercos de T. solium. Para la validación se realizaron 20 ensayos empleando controles positivos y negativos, por cuadruplicado en diferentes días, y realizados por más de un operador; el punto de corte para este método fue una densidad óptica de 0,325. La precisión intralaboratorio para el control débil (media=0,532±0,09) fue de %CV=17,51±0,09, y un valor de repetibilidad de %CV=7,04±0,04, cifras que se encuentran dentro de los límites esperados para el método. Con estos resultados se puede concluir que la precisión del ELISA para el serodiagnóstico de NCC se encuentra validada. El ensayo validado proporcionó resultados coherentes y repetidos que permitieron discriminar entre dos resultados dicotómicos y establecer con exactitud la condición de una posible infección, con un nivel de certidumbre estadística predeterminado.


Neurocysticercosis (NCC) is the location in the human central nervous system (CNS) of the parasitosis caused by the larval stage of Taenia solium, the cysticercus which prevails in urban and rural areas, constituting a public health problem. Diagnosis can be made by CNS imaging with magnetic resonance or computerized axial tomography, not always available, and by blood immunoassay (EIA) tests, which provide rapidity, low cost and transferability. In order to evaluate its diagnostic capacity and validate the ELISA (Enzyme- Linked ImmunoSorbent Assay) technique in the detection of anti-cysticercus antibodies in human sera, a collection of sera was designed in a randomized and double-blind manner, and the ELISA was performed with the samples, using plates sensitized with antigens obtained from the vesicular fluid of T. solium cysticerci. Twenty trials were conducted, using positive and negative controls, in quadruplicate, on different days, and performed by more than one operator; the cutoff for this method was an optical density of 0.325. The intralaboratory precision for the weak control (mean=0.532±0.09) was %CV=17.51±0.09, and a repeatability value of %CV=7.04±0.04, figures that are within the expected limits for the method, It can be concludedthat the accuracy of the ELISA for serodiagnosis of NCC is validated. The validated test provided consistent and repeated results, which made it possible to discriminate between two dichotomous outcomes, and to establish with accuracy the condition of a possible infection, with a predetermined level of statistical certainty.


A neurocisticercose (NCC) é o local no sistema nervoso central (SNC) humano de parasitose causada pelo estágio larval da Taenia solium, o cisticerco, prevalecente em áreas urbanas e rurais, constituindo um problema de saúde pública. O diagnóstico pode ser feito por varredura imagenológica do SNC com ressonância magnética ou tomografia axial computadorizada, nem sempre disponível, e por testes de imunoensaio (EIA) em sangue, que fornecem ao diagnóstico rapidez, baixo custo e portabilidade. Para avaliar a sua capacidade de diagnóstico e validar a precisão da técnica de ELISA (ensaio imunoabsorvente ligado a enzimas), na detecção de anticorpos anti-cisticercos em soros humanos, um serrarium foi projetado em forma aleatória e em duplo cego, e foi realizado com as amostras o ELISA, utilizando placas sensibilizadas com antígenos derivados do fluido vesicular de cisticercos de T. solium. 20 testes para validação foram realizados, utilizando controles positivos e negativos, em quadruplicado, em dias diferentes, e realizados por mais de um operador; o ponto de corte para este método era uma densidade óptica de 0,325. A precisão intralaboratorial para o controle fraco (média=0,532±0,09) foi de CV%=17,51±0,09, e um valor de repetibilidade de CV%=7,04±0,04, valores que estão dentro dos limites esperados para o método, podendo concluir com esses resultados que a precisão do ELISA para diagnóstico sorológico de NCC é validado. O ensaio validado forneceu resultados consistentes e repetidos, o que permitiu discriminar entre dois resultados dicotômicos e identificar com exatidão a condição de possível infecção com um nível de certeza pré-determinado estatisticamente.


Subject(s)
Humans , Cysticercosis/diagnosis , Neurocysticercosis/diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Taenia solium , Antibodies/blood
7.
Arch. endocrinol. metab. (Online) ; 63(4): 351-357, July-Aug. 2019. tab, graf
Article in English | LILACS | ID: biblio-1019365

ABSTRACT

ABSTRACT Objective In this study, we aimed to describe the prevalence and distribution of positive antithyroperoxidase antibodies (TPOAb) according to sex, age strata, and presence of thyroid dysfunction using baseline data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Materials and methods Thyroid hormone tests were obtained from each study participant at baseline. Levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) were measured using a third-generation immunoenzymatic assay. Antithyroperoxidase antibodies were measured by electrochemiluminescence and were considered to be positive when ≥ 34 IU/mL. Results The prevalence of TPOAb among 13,503 study participants was 12%. Of participants with positive TPOAb, 69% were women. Almost 60% of the individuals with positive TPOAb were white. The presence of positive TPOAb was associated with the entire spectrum of thyroid diseases among women, but only with overt hyperthyroidism and overt hypothyroidism in men. Conclusion The distribution of positive TPOAb across sex, race, age, and thyroid function in the ELSA-Brasil study is aligned with the worldwide prevalence of positive TPOAb reported in iodine-sufficient areas. In women, the presence of TPOAb was related to the entire spectrum of thyroid dysfunction, while in men, it was only related to the occurrence of overt thyroid disease.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Thyroid Diseases/epidemiology , Iodide Peroxidase/blood , Antibodies/blood , Thyroid Diseases/blood , Thyroxine/blood , Brazil/ethnology , Brazil/epidemiology , Thyrotropin/blood , Body Mass Index , Prevalence , Cross-Sectional Studies , Sex Distribution , Age Distribution , White People/statistics & numerical data
8.
Rev. bras. enferm ; 71(6): 3074-3083, Nov.-Dec. 2018. tab, graf
Article in English | LILACS, BDENF | ID: biblio-977608

ABSTRACT

ABSTRACT Objective: To identify biomarkers for Parkinson's disease, cerebrospinal fluid, blood, saliva, and urine. Method: The studies were collected from the Cochrane, LILACS, PubMed, SCOPUS, WEB OF SCIENCE, OpenGrey, ProQuest and Google Scholar databases starting from May 3, 2016 and updated on March 20, 2017. Twenty-two studies were evaluated, by the Quality Assessment Tool for Diagnostic Accuracy Studies and Review Manager 5.3. Results: Evidence shows that serum antibodies can be used as highly specific and accurate biomarkers for the diagnosis of Parkinson's disease at the outset. Biomarkers in the cerebrospinal fluid are related to increased motor severity, postural instability, gait abnormality, and cognitive impairment. Conclusion: Serum and cerebrospinal antibodies can be used as diagnostic biomarkers at the onset of the disease.


RESUMEN Objetivo: Identificar los biomarcadores para la enfermedad de Parkinson, el líquido cefalorraquídeo, la sangre, la saliva y la orina. Método: Los estudios fueron recolectados en las bases de datos Cochrane, LILACS, PubMed, SCOPUS, WEB OF SCIENCE, OpenGrey, ProQuest y Google Scholar, a partir del 3 de mayo de 2016 y actualizados el 20 de marzo de 2017. Se seleccionaron 22 estudios, evaluados por la Quality Assessment Tool for Diagnostic Accuracy Studies y el Review Manager 5.3. Resultados: La evidencia muestra que los anticuerpos séricos pueden ser utilizados como biomarcadores altamente específicos y precisos para el diagnóstico de la enfermedad de Parkinson en su inicio. Los biomarcadores en el líquido cefalorraquídeo están relacionados con el aumento de la severidad motora, la inestabilidad postural, el disturbio de la marcha y la declinación cognitiva. Conclusión: Los anticuerpos séricos y cefalorraquídeos pueden utilizarse como biomarcadores de diagnóstico al inicio de la enfermedad.


RESUMO Objetivo: Identificar os biomarcadores para a doença de Parkinson, no líquido cefalorraquidiano, sangue, saliva e urina. Método: Os estudos foram coletados nas bases de dados Cochrane, LILACS, PubMed, SCOPUS, WEB OF SCIENCE, OpenGrey, ProQuest e Google Scholar, a partir de 3 de maio de 2016 e atualizados em 20 de março de 2017. Foram selecionados 22 estudos, avaliados pelo Quality Assessment Tool for Diagnostic Accuracy Studies e o Review Manager 5.3. Resultados: A evidência mostra que os anticorpos séricos podem ser usados como biomarcadores altamente específicos e precisos para o diagnóstico da doença de Parkinson em seu início. Os biomarcadores no líquido cefalorraquidiano estão relacionados ao aumento da severidade motora, à instabilidade postural, ao distúrbio da marcha e ao declínio cognitivo. Conclusão: Os anticorpos séricos e cefalorraquidianos podem ser utilizados como biomarcadores de diagnóstico no início da doença.


Subject(s)
Humans , Parkinson Disease/diagnosis , Biomarkers/analysis , Sensitivity and Specificity , Parkinson Disease/blood , Biomarkers/blood , Antibodies/analysis , Antibodies/blood
9.
Medicina (B.Aires) ; 78(supl.2): 88-93, set. 2018. ilus, tab
Article in Spanish | LILACS | ID: biblio-955021

ABSTRACT

Las encefalitis autoinmunes son un nuevo grupo de enfermedades de gran trascendencia clínica y terapéutica debido a la buena respuesta en gran parte de los casos a la terapia inmunomoduladora indicada, con un gran porcentaje de curación, sin secuelas neurológicas importantes (cognitivo, motor, crisis o movimientos involuntarios). En el año 2007 se demostró la presencia de auto anticuerpos neuronales en la patogenia de este grupo de enfermedades, con síntomas psicóticos y de movimientos involuntarios como indicadores de la enfermedad. La presente revisión enfatiza el salto crucial y el cambio de paradigmas suscitados tras el descubrimiento de estas encefalitis asociadas a anticuerpos.


Autoimmune encephalitis is a new group of diseases of great clinical and therapeutic importance due to the good response in most cases to the immunomodulatory therapy indicated, with a large percentage of healing without significant neurological effects (cognitive, motor, seizures or involuntary movements). Since 2007, the presence of neuronal autoantibodies in the pathogenesis of this group of diseases has been demonstrated, with psychotic symptoms and involuntary movements as clinical markers of the disease. The present review emphasizes the crucial leap and change of paradigms arising after the discovery of these encephalitis associated with antibodies.


Subject(s)
Humans , Autoimmune Diseases/diagnosis , Encephalitis/diagnosis , Hashimoto Disease/diagnosis , Autoantibodies/blood , Autoimmune Diseases/drug therapy , Methylprednisolone/therapeutic use , Biomarkers/blood , Neuroprotective Agents/therapeutic use , Encephalitis/drug therapy , Hashimoto Disease/drug therapy , Hashimoto Disease/blood , Rituximab/therapeutic use , Antibodies/blood
10.
Arq. gastroenterol ; 55(2): 192-197, Apr.-June 2018. tab, graf
Article in English | LILACS | ID: biblio-950506

ABSTRACT

ABSTRACT BACKGROUND: Infliximab (IFX) therapeutic drug monitoring is an important tool to guide therapeutic decision in inflammatory bowel disease patients. Currently, there are two methods to measure trough levels of IFX, ELISA assays or rapid tests. Despite that the ELISA assay is the most used method in therapeutic drug monitoring, the results take long to be available for clinical use, and it needs to be performed by trained personnel. In contrary, the results of a rapid test take 20 to 30 minutes to be available and can be performed by non-trained lab personnel. OBJECTIVE: The aim of the study was to compare a rapid test (QB-IFX) for quantitative determination of IFX level to one ELISA assay in a cohort of inflammatory bowel disease patients. METHODS: Cross-sectional multicentric study with 49 inflammatory bowel disease patients on maintenance therapy with IFX. Blood samples for IFX serum levels were collected immediately before infusion. IFX serum levels were classified as undetectable, low (<3.0 μg/mL), adequate (3.1-7.0 μg/mL) or high (>7.1 μg/mL). A sensitivity and specificity of each test and a comparison between tests was based on ROC curves. RESULTS: Thirty-four Crohn's disease patients and 15 ulcerative colitis patients in clinical remission were evaluated. The majority of patients had low or adequate serum levels of IFX. In relation to the serum levels proportions with the two methods, there was no significant difference (P=0.84). The ROC analysis identified a concentration threshold >2.9 μg/mL with the QB-IFX test (area under the ROC, 0.82; P<0.0001, sensitivity, 100%; specificity, 61.9%), and >3.83 μg/mL using the ELISA assay (area under the ROC, 0.96; P<0.0001, sensitivity, 100%; specificity, 92.9%). CONCLUSION: QB-IFX and ELISA assays to measure IFX levels were comparable. Both methods had accurate sensitivity and specificity to detect undetectable, low and adequate levels, but had showed low specificity for supra therapeutic levels of IFX.


RESUMO CONTEXTO: A monitorização dos níveis séricos do infliximabe (IFX) é uma importante ferramenta para guiar a tomada de decisão nos pacientes com doença inflamatória intestinal. No presente momento existem dois tipos de métodos para quantificar nível sérico de IFX disponíveis no mercado: o ELISA e o teste rápido. O método ELISA é o mais usado em todo o mundo, todavia os resultados demoram de 1 a 2 dias para estar disponíveis para uso clínico. Além disso, o ELISA é um método que requer um técnico especializado para realizá-lo. Ao contrário, os resultados do teste rápido estão disponíveis em 20 a 30 minutos e esse pode ser realizado por um funcionário não especializado. OBJETIVO: O objetivo deste estudo foi comparar o teste rápido (QB-IFX) com o teste ELISA para determinação quantitativa do nível sérico de IFX em uma coorte de pacientes com doença inflamatória intestinal. MÉTODOS: Foi realizado um estudo transversal multicêntrico com inclusão de 49 pacientes em terapia de manutenção com IFX. Amostra sanguínea para dosagem sérica do IFX foi coletada imediatamente antes da infusão. A dosagem sérica do IFX foi classificada em indetectável, baixo (<3,0 μg/mL), adequado (3,1-7,0 μg/mL) ou alto (>7,1 μg/mL). A sensibilidade e a especificidade de cada teste e a comparação entre os testes foram avaliados através de curva ROC. RESULTADOS: Foram avaliados 34 pacientes com doença de Crohn e 15 pacientes com retocolite ulcerativa em remissão clínica da doença. A maioria dos pacientes apresentou níveis baixos ou adequados do IFX sérico de acordo com ambos os métodos de dosagem. Não houve diferença significativa entre os métodos quando avaliados categoricamente (P=0,84). A análise da curva ROC identificou limites de concentrações >2,9 μg/mL com o teste rápido QB-IFX (AUC ROC, 0,82; P<0,0001, sensibilidade: 100%; especificidade: 61.9%), e >3,83 μg/mL usando o método ELISA (AUC ROC, 0,96; P<0,0001, sensibilidade: 100%; especificidade: 92,9%). CONCLUSÃO: Os testes QB-IFX e ELISA foram comparáveis para dosagem do nível sérico de IFX. Ambos os métodos são acurados e apresentaram boa sensibilidade e especificidade para detecção de níveis indetectáveis, níveis baixos e níveis adequados, porém mostraram pouca especificidade para níveis supra terapêuticos da droga.


Subject(s)
Humans , Male , Female , Adult , Young Adult , Gastrointestinal Agents/blood , Enzyme-Linked Immunosorbent Assay , Colitis, Ulcerative/blood , Crohn Disease/blood , Infliximab/blood , Biomarkers/blood , Cross-Sectional Studies , ROC Curve , Cohort Studies , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Drug Monitoring , Age of Onset , Middle Aged , Antibodies/blood
11.
An. bras. dermatol ; 93(2): 212-215, Mar.-Apr. 2018. tab, graf
Article in English | LILACS | ID: biblio-887198

ABSTRACT

Abstract: Background: Previous studies have shown oxidative stress in pemphigus vulgaris and pemphigus foliaceus, nevertheless, it remains unknown whether a similar response is characteristic of endemic pemphigus foliaceus in Peru. Objectives: To determine the oxidative stress response in endemic pemphigus foliaceus patients and subjects with positive for anti-desmoglein1 antibodies (anti-dsg1) from endemic areas of Peru. Subjects and Methods: This is a cross-sectional study. The study population included 21 patients with Endemic Pemphigus foliaceus and 12 healthy subjects with anti-dsg1 antibodies from the Peruvian Amazon (Ucayali), as well as 30 healthy control subjects. Malondialdehyde, an indicator of lipid peroxidation by free radicals, was measured in serum. Results: We collected 21 cases of endemic pemphigus foliaceus, 15 of them with active chronic disease and 6 in clinical remission. Serum malondialdehyde values in patients with chronic active evolution and healthy subjects with anti-dsg1 antibodies were statistically higher than those of healthy controls (p<0.001). There was no significant difference between serum values of localized and generalized clinical forms. Study limitations: The main limitation of this present study is the small number of patients with endemic pemphigus and healthy subjects positive for desmoglein 1 antibodies. Conclusions: The increased serum levels of malondialdehyde in patients with chronic active endemic pemphigus foliaceus and healthy subjects from endemic areas with anti-dsg1 antibodies may suggest a contribution of systemic lipid peroxidation in the pathogenesis of endemic pemphigus foliaceus.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Pemphigus/immunology , Pemphigus/metabolism , Oxidative Stress/physiology , Desmoglein 1/immunology , Malondialdehyde/blood , Antibodies/blood , Peru , Reference Values , Remission, Spontaneous , Enzyme-Linked Immunosorbent Assay , Lipid Peroxidation/physiology , Case-Control Studies , Cross-Sectional Studies , Statistics, Nonparametric , Endemic Diseases , Desmoglein 1/blood
12.
Mem. Inst. Oswaldo Cruz ; 112(2): 116-122, Feb. 2017. tab, graf
Article in English | LILACS, SES-SP | ID: biblio-841765

ABSTRACT

BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients. METHODS cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of São Paulo state, using enzyme-linked immunosorbent assay. FINDINGS Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN CONCLUSION High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.


Subject(s)
Animals , Male , Female , Rabbits , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/blood , Insect Proteins/immunology , Insect Vectors/classification , Antibodies/immunology , Antibodies/blood , Psychodidae/chemistry , Brazil , Enzyme-Linked Immunosorbent Assay , Immunoblotting , Case-Control Studies , Polymerase Chain Reaction , Insect Proteins/analysis , Endemic Diseases
13.
Pesqui. vet. bras ; 36(12): 1155-1159, Dec. 2016. tab
Article in English | LILACS, VETINDEX | ID: biblio-842035

ABSTRACT

In order to investigate the immune enhancement effects of Ophiopogon japonicus polysaccharide Ophiopogon japonicus (OJPS) on Newcastle disease (ND) live vaccine, chickens vaccinated against ND live vaccine was orally administered with the OJPS at high, medium and low concentrations respectively. In negative control group, chickens were given orally equal volume of physiological saline. On day 14, 21 and 28, the serum antibody titer, erythrocyte-C3b receptor rosette rate (E-C3bRR), erythrocyte-C3b immune complex rosette rate (E-ICRR) and peripheral lymphocyte proliferation were measured. The results showed that at most time points, the antibody titer, peripheral lymphocyte proliferation, E-C3bRR and elimination rate of immune complex of three OJPS administrating groups were significantly higher (P<0.05) than those in negative control group. It indicated that OJPS could significantly improve the immune efficacy of Newcastle disease live vaccine, Ophiopogon japonicus polysaccharide possessed synergistical immunoenhancement.(AU)


Subject(s)
Animals , Chickens/virology , Newcastle Disease/immunology , Ophiopogon/chemistry , Viral Vaccines/analysis , Adjuvants, Immunologic , Antibodies/blood , Erythrocytes/immunology , Lymphocytes/immunology
14.
Bogotá; IETS; mayo 2016. 33 p. tab.
Monography in Spanish | BRISA, LILACS | ID: biblio-846831

ABSTRACT

Tecnologías evaluadas: Nueva: anticuerpos antipéptidos cíclicos citrulinados; Actual: Factor reumatoide. Población: Pacientes mayores de 16 años con artritis reumatoide en Colombia. Perspectiva: La perspectiva del presente AIP corresponde al tercero pagador, que en este caso es el Sistema General de Seguridad Social en Salud (SGSSS) en Colombia. Horizonte temporal: El horizonte temporal de este AIP en el caso base corresponde a un año. Adicionalmente se reportan las estimaciones del impacto presupuestal para los años 2 y 3, bajo el supuesto de la inclusión en el POS en el año 1. Costos incluidos: Costos de las tecnologías analizadas. Fuente de costos: Los precios de cada tecnología considerada fueron\r\nconsultados en el manual tarifario ISS 2001 y ajustados con un +25%, +30% y +48%. Los precios de las consultas médicas fueron consultados en el manual tarifario ISS 2001 y ajustados con un +30%. Escenarios: \r\nEn tanto el escenario 1 como el escenario 2 se asume que la adopción de las nuevas tecnologías resultará en que su participación de mercado equilibraría debido a la preferencia de los clínicos de utilizar la combinación de tanto la tecnología actual con la tecnología nueva. Resultados: Se necesitaría una inversión de $11.136.331.800,00 para el año 1, $12.624.171.516,00 para el año 2 y 14.436.417.841,56 para el año 3 para la inclusión de la prueba anti-CCP en el POS para pacientes con artritis reumatoide mayores de 16 años en Colombia, bajo el presupuesto que la adopción de la nueva tecnología llevaría a un cambio en la participación del mercado.(AU)


Subject(s)
Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Peptides, Cyclic/analysis , Arthritis, Rheumatoid/diagnosis , Citrulline/analysis , Antibodies/blood , Colombia , Costs and Cost Analysis/methods , Biomedical Technology
15.
Mem. Inst. Oswaldo Cruz ; 110(6): 726-731, Sept. 2015. tab, graf
Article in English | LILACS | ID: lil-763099

ABSTRACT

The protective effect of infectious agents against allergic reactions has been thoroughly investigated. Current studies have demonstrated the ability of some helminths to modulate the immune response of infected hosts. The objective of the present study was to investigate the relationship between Toxocara canis infection and the development of an allergic response in mice immunised with ovalbumin (OVA). We determined the total and differential blood and bronchoalveolar lavage fluid cells using BALB/c mice as a model. To this end, the levels of interleukin (IL)-4, IL-5 and IL-10 and anti-OVA-IgE were measured using an ELISA. The inflammatory process in the lungs was observed using histology slides stained with haematoxylin and eosin. The results showed an increase in the total number of leukocytes and eosinophils in the blood of infected and immunised animals at 18 days after infection. We observed a slight lymphocytic inflammatory infiltrate in the portal space in all infected mice. Anti-OVA-IgE levels were detected in smaller proportions in the plasma of immunised and infected mice compared with mice that were only infected. Therefore, we concluded that T. canis potentiates inflammation in the lungs in response to OVA, although anti-OVA-IgE levels suggest a potential reduction of the inflammatory process through this mechanism.


Subject(s)
Animals , Bronchoalveolar Lavage Fluid/parasitology , Hypersensitivity/parasitology , Lung/immunology , Toxocara canis/immunology , Toxocariasis/immunology , Antibodies/blood , Biopsy , Enzyme-Linked Immunosorbent Assay , Eosinophils/parasitology , Immunoglobulin E/blood , Inflammation/physiopathology , Interleukin-10/blood , Interleukin-4/blood , Interleukin-5/blood , Leukocyte Count , Lung/pathology , Mice, Inbred BALB C , Ovalbumin/immunology , Toxocariasis/blood
16.
Rev. bras. neurol ; 51(2): 45-47, abr.-jun. 2015. ilus
Article in English | LILACS | ID: lil-761195

ABSTRACT

Glutamic acid decarboxylase (GAD) is the enzyme responsible for the conversion of glutamate to gamma-aminobutyric acid (GABA) in the central nervous system. The presence of anti-GAD antibody in cerebrospinal fluid and high levels in blood have been described in some neurological disorders, such as stiff person syndrome and cerebellar ataxia. It is postulated that African descent with anti-GAD may exhibit more severe neurological impairment. We report a case of a young adult African descent with cerebellar syndrome associ-ated with ophthalmoplegia and laryngeal stridor. We found in the literature relationship of ophthalmoplegia plus ataxia with anti-GAD, but no reports of these symptoms with laryngeal stridor, apparently being the first reported case.


Descarboxilase do ácido glutâmico (GAD) é a enzima responsável pela conversão do glutamato em ácido gama-aminobutírico (GABA) no sistema nervoso central. A presença do anticorpo anti-GAD no líquido cefalorraquidiano e em altos níveis no sangue tem sido descrita em alguns distúrbios neurológicos, tais como a síndrome da pessoa rígida e ataxia cerebelar. Postula-se que pacientes afrodescendentes podem apresentar comprometimento neurológico mais severo. Relatamos o caso de um adulto jovem afrodescendente com síndrome cerebelar associada a oftalmoplegia e estridor laríngeo. Encontramos na literatura relação entre a oftalmoplegia com ataxia e anti-GAD, mas nenhum relato desses sintomas com estridor laríngeo, sendo aparentemente o primeiro caso reportado.


Subject(s)
Humans , Male , Young Adult , Cerebellar Ataxia/diagnosis , Ophthalmoplegia/diagnosis , Respiratory Sounds , Glutamate Decarboxylase/immunology , Gait Ataxia/diagnosis , Glutamate Decarboxylase/blood , Antibodies/blood , Neurologic Examination/statistics & numerical data
17.
Conscientiae saúde (Impr.) ; 14(1): 11-23, 31 mar. 2015.
Article in English | LILACS | ID: biblio-633

ABSTRACT

Introduction: Common variable immunodeficiency (CVID) is an immunological disorder characterized by defective antibody production. Objectives: To study lymphocytes number, surface activation molecules, cell markers, lymphoproliferative response, cytokine production, and cell death. Methods: A study was led on thirty four patients with CVID selected from the Division of Clinical Immunology and Allergies of the Faculty of Medicine of São Paulo University (FMUSP), Brazil. Peripheral mononuclear blood cells (PBMC) of CVID patients and healthy individuals were evaluated in regard to the expression of cell surface markers, activation molecules, lymphoproliferative response, cytokine synthesis and apoptosis. Results: CVID patients showed decrease in T and B lymphocyte counts, CD25, CD69, CD40L, and CD70 expression, and low synthesis levels of IL-4 and IL-5. Furthermore, their lymphocytes were more susceptible to apoptosis following activation. Conclusion: The higher susceptibility to apoptosis following activation may also be responsible for the decrease in the expression of activation molecules and CD40L, in cytokine synthesis, and in levels of circulating T and B cells.


Introdução: A imunodeficiência comum variável (CVID) é uma enfermidade imune caracterizada pela produção deficiente de anticorpos. Objetivo: Avaliar o número de linfócitos, moléculas de ativação, resposta linfoproliferativa, produção de citocinas e morte celular. Métodos: Foram selecionados 34 pacientes com CVID na Divisão de Imunologia Clínica e Alergia da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Brasil. Células mononucleares obtidas a partir de sangue periférico (PBMC) foram isoladas para avaliação de marcadores de superfície celular, moléculas de ativação, resposta linfoproliferativa, quantificação de citocinas e apoptose. Resultados: Os pacientes analisados apresentaram diminuição na contagem de linfócitos T e B, expressão de CD25, CD69, CD40L, CD70, e baixa produção de IL-4 e IL-5. Os linfócitos se apresentaram mais suscetíveis à apoptose pós-ativação. Conclusão: A maior susceptibilidade à apoptose pós-ativação pode ser responsável pela diminuição na expressão de moléculas de ativação e CD40L, síntese de citocinas e linfócitos T e B circulantes.


Subject(s)
Humans , Common Variable Immunodeficiency/blood , Apoptosis , Antibodies/blood , B-Lymphocytes , T-Lymphocytes , Case-Control Studies , Cytokines , Cell Death , Signaling Lymphocytic Activation Molecule Family
18.
Annals of Laboratory Medicine ; : 314-320, 2015.
Article in English | WPRIM | ID: wpr-36808

ABSTRACT

BACKGROUND: Angiotensin II type 1 receptor (AT1R) is responsible for cardiovascular effects mediated by angiotensin II. This study aimed to investigate the impact of antibodies directed against AT1R (anti-AT1R) in renal allograft rejection. METHODS: We evaluated 53 patients who had biopsy-proven rejection including antibody-mediated rejection (AMR) (N=22), T-cell-mediated rejection (TCMR) (N=29), and mixed AMR and TCMR (N=2). Donor specific HLA antibodies (DSA) and anti-AT1Rs were simultaneously determined. RESULTS: Anti-AT1Rs were detected in 9.4% (5/53) of rejection patients (one with acute AMR, two with chronic active AMR, one with acute TCMR, and one with mixed acute AMR & TCMR). HLA antibodies and DSA were detected in 75.5% (40/53) and 49.1% (26/53) of patients, respectively. There was no significant difference in transplant characteristics between anti-AT1R(+) and anti-AT1R(-) patients except for the association of HLA class-I DSA(+) and anti-AT1R(+). Four of five anti-AT1R(+) patients had DSA and were also found to have AMR. A single anti-AT1R(+)/DSA(-) patient developed acute TCMR. Detection rates of DSA, HLA antibodies, or anti-AT1R were not different between AMR and TCMR. However, DSA(+)/anti-AT1R(+) was more frequently found in AMR than in TCMR (P=0.036). Patients with anti-AT1R showed a greater tendency to develop high-grade rejection as Banff IIA/IIB or AMR. CONCLUSIONS: The presence of anti-AT1R was significantly associated with HLA class-I DSA in renal allograft rejection patients. Both anti-AT1R and DSA positivity was associated with AMR in patients with renal allograft rejection.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Antibodies/blood , Graft Rejection/etiology , HLA Antigens/immunology , Kidney/pathology , Kidney Transplantation/adverse effects , Receptor, Angiotensin, Type 1/immunology , Tissue Donors , Transplantation, Homologous
19.
Annals of Laboratory Medicine ; : 611-617, 2015.
Article in English | WPRIM | ID: wpr-76933

ABSTRACT

BACKGROUND: Anti-Gal is a major antibody induced in non-human primates (NHPs) after xenotransplantation. To understand the mechanism of graft rejection, we investigated the association between anti-Gal responses and graft failure in NHP recipients of porcine islet transplantation (PITx). METHODS: Intraportal PITx was performed in 35 diabetic NHPs, and graft function was monitored. Early graft failure (EGF) was defined as loss of graft function within a month after PITx. Seven, 19, nine NHPs received immunosuppression (IS) without CD40 pathway blockade (Group I), with anti-CD154 (Group II), and with anti-CD40 (Group III), respectively. The anti-Gal levels on day 0 and day 7 of PITx were measured by ELISA. RESULTS: The frequency of EGF was significantly lower in Group II (26.3%) than in Group I (100%, P=0.0012) and Group III (77.8%, P=0.0166). While levels of anti-Gal IgG in Group I and anti-Gal IgM in Group III increased on day 7 compared with day 0 (P=0.0156 and 0.0273), there was no increase in either on day 7 in Group II. The ratio of anti-Gal IgM or IgG level on day 7 to that on day 0 (Ratio7/0) was significantly higher in recipients with EGF than without EGF (P=0.0009 and 0.0027). ROC curve analysis of anti-Gal IgM Ratio7/0 revealed an area under the curve of 0.789 (P=0.0003). CONCLUSIONS: IS with anti-CD154 suppressed anti-Gal responses and prevented EGF in PITx. Anti-Gal IgM Ratio7/0, being associated with EGF, is a predictive marker for EGF.


Subject(s)
Animals , Antibodies/blood , CD40 Antigens/immunology , Area Under Curve , CD40 Ligand/immunology , Disaccharides/immunology , Epidermal Growth Factor/blood , Graft Rejection/immunology , Immunoglobulin G/blood , Immunoglobulin M/blood , Immunosuppressive Agents/therapeutic use , Islets of Langerhans Transplantation , Macaca mulatta , ROC Curve , Swine , Transplantation, Heterologous
20.
Yonsei Medical Journal ; : 1545-1551, 2015.
Article in English | WPRIM | ID: wpr-177071

ABSTRACT

PURPOSE: Elastin is a major arterial structural protein, and elastin-derived peptides are related to arterial change. We previously reported on a novel assay developed using aortic elastin peptides; however, its clinical implications remain unclear. In this study, we assessed whether anti-elastin antibody titers reflect the risk of coronary artery disease (CAD) or its characteristics. MATERIALS AND METHODS: We included 174 CAD patients and 171 age- and sex-matched controls. Anti-elastin antibody titers were quantified by enzyme-linked immunosorbent assay. Parameters of arterial stiffness, including the augmentation index (AI) and heart-to-femoral pulse wave velocity (hfPWV), were measured non-invasively. The clinical and angiographic characteristics of CAD patients were also evaluated. Associations between anti-elastin levels and vascular characteristics were examined by linear regression analysis. RESULTS: The median blood level of anti-elastin was significantly lower in the CAD group than in the controls [197 arbitrary unit (a.u.) vs. 63 a.u., p<0.001]. Levels of anti-elastin were significantly lower in men and in subjects with hypertension, diabetes mellitus, hyperlipidemia, or high hfPWV. Nevertheless, anti-elastin levels were not dependent on atherothrombotic events or the angiographic severity of CAD. In a multivariate analysis, male sex (beta=-0.38, p<0.001), diabetes mellitus (beta=-0.62, p<0.001), hyperlipidemia (beta=-0.29, p<0.001), and AI (beta=-0.006, p=0.02) were ultimately identified as determinants of anti-elastin levels. CONCLUSION: Lower levels of anti-elastin are related to CAD. The association between antibody titers and CAD is linked to arterial stiffness rather than the advancement of atherosclerosis.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Angiography , Antibodies/blood , Atherosclerosis/blood , Coronary Artery Disease/blood , Elastin/blood , Enzyme-Linked Immunosorbent Assay , Hyperlipidemias , Hypertension/complications , Pulse Wave Analysis , Vascular Stiffness/immunology
SELECTION OF CITATIONS
SEARCH DETAIL